Search the Newsreel

State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD

The State of Wyoming recently acquired 9,446 shares of Revolution Medicines, Inc. (NASDAQ:RVMD) valued at approximately $1.77 million, marking a new position in the biopharmaceutical company. This move comes as institutional investors and hedge funds collectively hold 94.34% of RVMD's stock. Despite a recent …

Cincinnati Financial Corporation $CINF Stock Holdings Lessened by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC reduced its stake in Cincinnati Financial Corporation (NASDAQ:CINF) by 31.3% in the second quarter, selling 55,054 shares and holding 120,995 shares worth $22.4 million. Despite this, other institutional investors like North Dakota State Investment Board and 71 West Capital Partners …

Oppenheimer Asset Management Inc. Purchases Shares of 29,235 Cintas Corporation $CTAS

Oppenheimer Asset Management Inc. recently acquired 29,235 shares of Cintas Corporation (NASDAQ:CTAS) worth approximately $4.97 million, contributing to institutional investors owning 63.46% of the company. Cintas reported strong quarterly earnings, surpassing expectations with $1.29 EPS and $2.91 billion in revenue, and increased its quarterly …

21,792 Shares in Cintas Corporation $CTAS Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP recently purchased 21,792 shares of Cintas Corporation (NASDAQ:CTAS), valued at approximately $3.706 million, during the second quarter. Other institutional investors like Brighton Jones LLC, Sivia Capital Partners LLC, and Ieq Capital LLC also increased their holdings in Cintas. The company …

Helios Capital Management PTE. Ltd. Acquires Shares of 6,800 Cintas Corporation $CTAS

Helios Capital Management PTE. Ltd. has acquired 6,800 shares of Cintas Corporation (NASDAQ:CTAS) during the second quarter, valued at approximately $1,157,000, making it their 20th largest holding. Other institutional investors like State Street Corp, Geode Capital Management LLC, and Norges Bank also increased their …

9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB recently acquired 9,840 shares of Praxis Precision Medicines (NASDAQ:PRAX) valued at approximately $3.29 million, contributing to institutional investors owning 67.84% of the company. Praxis Precision Medicines reported a smaller-than-expected quarterly loss of $2.87 per share and holds a consensus "Buy" rating …

Price to earnings forward of Morabaha Marina Financing Company – TADAWUL:4082

Cintas Executive Sells Shares for Tax Obligations

Cintas CFO Scott Garula sold 2,958 shares worth approximately $600,000 on August 10 to cover tax obligations from vested restricted stock. Despite this sale, Garula maintains a significant holding of 105,495 direct shares, valued at about $21.4 million, signaling continued confidence in the company. …

Top Generate Biomedicines (GENB) Competitors 2026

Cintas's UniFirst Deal Is Approved — So Why Is the Arbitrage Spread Still 7.8%?

Despite shareholder approval, UniFirst Corporation (UNF) still trades at a significant discount to Cintas Corporation's (CTAS) acquisition offer, indicating market concerns over potential antitrust review due to the combined entity's estimated 50% North American market share. Cintas's strategic rationale for the deal is to …

Cintas Executive Chairman Sells 15,923 Shares

Cintas Executive Chairman Scott D. Farmer sold 15,923 shares for $3.2 million on August 10 to cover tax obligations, a transaction that does not reflect his view on the stock. Despite a 10% decline in stock price over the past year, Cintas reported 8.9% …

Why Has Cintas Stock Slipped Despite Record Margins? What to Know Amid a Founder's Vesting

Executive Chairman Scott D. Farmer disposed of 15,923 shares of Cintas Corporation (NASDAQ:CTAS) at $202.71 per share on August 10, according to a recent SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 15,923 Transaction value $3.2 million Post-transaction shares (directly held) …

What a Cintas CEO Insider Filing Signals as It Pursues UniFirst

Todd M. Schneider, the CEO of Cintas Corporation (NASDAQ:CTAS), disposed of 35,599 shares of common stock on August 10, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold 35,599 Transaction value $7.2 million Post-transaction shares (directly held) 691,407 Post-transaction shares …

CINF.GD Bond Risk Profile

This page provides a bond risk profile for Cincinnati Financial Corporation's 6.125% bond maturing on November 1, 2034, identified as CINF.GD. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate the bond's reliability. …

TD Asset Management Inc Sells 8,813 Shares of Cincinnati Financial Corporation $CINF

TD Asset Management Inc. significantly reduced its stake in Cincinnati Financial Corporation (NASDAQ:CINF) during the second quarter, selling 8,813 shares and retaining 54,270 shares valued at approximately $10.05 million. Despite institutional investors collectively owning 65.24% of the company, Cincinnati Financial's recent earnings of $1.43 …

5,584 Shares in Cintas Corporation $CTAS Purchased by Summit Global Investments

Summit Global Investments recently acquired 5,584 shares of Cintas Corporation (NASDAQ:CTAS), valued at approximately $950,000, during the second quarter. Other institutional investors also made significant moves in Cintas stock, highlighting continued interest in the business services provider. Analysts have largely maintained positive ratings for …

Cingulate (NASDAQ:CING) Upgraded by Wall Street Zen to "Sell" Rating

Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News

The article provides information related to Parabilis Medicines (PBLS) stock options chain, including quotes and news. The content itself is not available in the provided input.

Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside

The average 12-month price target for Prime Medicine, Inc. (PRME) stock has been lowered from $7.12 to $6.92 by 9 analysts, yet this new target still suggests a significant 124% potential upside from its August 14th closing price. The consensus rating for PRME remains …

Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells 804 Shares

Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu recently sold 804 shares of the company's stock for $66,442.56, reducing his total holdings by 1.46%. This sale is part of a series of insider transactions since mid-June. Despite these sales, the company exceeded its recent quarterly …

Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ

Disc Medicine COO Jonathan Yu sells $66,444 in shares By Investing.com

Disc Medicine's COO, Jonathan Yu, sold 804 shares of the company's common stock for a total of $66,444 at an average price of $82.6425. This transaction was part of a pre-arranged trading plan, and it occurred as the stock had seen a 41% return …

Disc Medicine (NASDAQ: IRON) COO trades 804 shares via 10b5-1 plan

Disc Medicine's COO, Yu Jonathan Yen-Wen, exercised stock options for 804 shares at $13.50 each and simultaneously sold these 804 shares at a weighted average price of $82.6425. These transactions, which generated an approximate pre-tax spread of $56,000, were conducted under a pre-arranged Rule …

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution's four clinical-stage RAS(ON) inhibitors to evaluate …

nCino (NCNO): Buy, Sell, or Hold Post Q1 Earnings?

nCino (NCNO): Buy, Sell, or Hold Post Q1 Earnings? nCino has had an impressive run over the past six months as its shares have beaten the S&P 500 by 7.4%. The stock now trades at $19.16, marking a 20.9% gain. This was partly due …

Cineverse (CNVS): Corsair Capital group discloses 3.9% ownership stake in 13G/A

A group of investors affiliated with Corsair Capital has reported a 3.9% beneficial ownership stake in Cineverse Corp. (CNVS) through a Schedule 13G/A filing. This collective ownership amounts to 920,150 shares of Class A Common Stock out of 23,417,021 shares outstanding as of June …

Cinemark Holdings (CNK) director receives 5,439-share restricted stock grant

Cinemark Holdings director Steve Rosenberg received an annual award of 5,439 shares of restricted Common Stock on June 15, 2026, as part of the company's director compensation policy. This grant, with a par value of $0.001 per share and no purchase price, increases his …

Cinemark (CNK) director granted 5,439 restricted shares, holdings now 87,428

Cinemark Holdings, Inc. director Carlos M. Sepulveda was granted 5,439 restricted common shares on June 15, 2026, as part of the company's director compensation policy. This award, with a par value of $0.001 per share, increased his direct holdings to 87,428 shares. The transaction …

Cinemark Holdings (CNK) awards 5,439 restricted shares to director Loewe

Cinemark Holdings, Inc. (CNK) director Nancy S. Loewe was granted 5,439 restricted shares of common stock on June 15, 2026, as an annual award under the company's director compensation policy. This transaction increased her direct holdings to 55,028 shares. The shares have a par …

Cinevista Ltd Reports Very Positive Financial Trend Amid Margin Expansion

Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines

Baker Bros. Advisors LP and related entities have reported a passive ownership stake of 5.3% in Revolution Medicines, Inc. This translates to beneficial ownership of 11,443,357 shares of common stock, held through investment funds Baker Brothers Life Sciences, L.P. and 667, L.P. The filing …

Cineverse (NASDAQ: CNVS) posts 175% Q1 revenue surge and reaffirms 2027 outlook

Cineverse Corp. (NASDAQ: CNVS) reported a 175% increase in Q1 FY 2027 revenue to $30.6 million, largely due to recent acquisitions in advertising technology and media services, and a positive Adjusted EBITDA of $0.5 million. Despite a widened net loss, the company reaffirmed its …

Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership

ARCH Venture Fund XII and related entities have disclosed a 5.3% beneficial ownership stake in Parabilis Medicines (PBLS), amounting to 6,412,780 shares of common stock. This Schedule 13G filing indicates a passive investment, with ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, …